TrialAmerican journal of hematology2013

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.

J Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.